Note: Descriptions are shown in the official language in which they were submitted.
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
PROTEASE CONJUGATES FIAVING
STERICALLY PROTECTED EPITOPE REGIONS
FIELD OF THE INVENTION
The present invention relates to chemically modified subtilisin proteases
which are useful
in compositions such as, for example, personal care compositions., laundry
compositions, hard
surface cleansing compositions, and light duty cleaning compositions.
BACKGROUND OF THE INVENTION
Enzymes make up the largest class of naturally occurring proteins. One class
of enzyme
includes proteases which catalyze the hydrolysis of other proteins. This
ability to hydrolyze
proteins has typically been exploited by incorporating naturally occurring and
genetically
engineered proteases into cleaning compositions, particularly those relevant
to laundry
applications.
In the cleaning arts, the mostly widely utilized of these proteases are the
serine proteases.
Most of these serine proteases are produced by bacterial organisms while some
are produced by
other organisms, such as fungi. See Siezen et al., "Homology Modelling and
Protein Engineering
Strategy of Subtilases, the Family of Subtilisin-Like Serine Proteases",
Protein Engineering, Vol.
4, No. 7, pp. 719 - 737 (1991). Unfortunately, the efficacy of the wild-type
proteases in their
natural environment is frequently not optimized for the artificial environment
of a cleaning
composition. Specifically, protease characteristics such as, for example,
thermal stability, pH
stability, oxidative stability, and substrate specificity are not necessarily
optimized for utilization
outside the natural environment of the protease.
Several approaches have been employed to alter the wild-type amino acid
sequence of
serine proteases with the goal of increasing the efficacy of the protease in
the unnatural wash
environment. These approaches include the genetic redesign and / or chemical
modification of
proteases to enhance thermal stability and to improve oxidation stability
under quite diverse
conditions.
However, because such modified proteases are foreign to mammals, they are
potential
antigens. As antigens, these proteases cause an immunogenic and / or
allergenic response (herein
collectively described as immunogenic response) in mammals.
Furthermore, while genetic redesign and chemical modification of proteases has
been
prominent in the continuing search for more highly effective proteases for
laundry applications,
such proteases have not been commercially utilized in personal care
compositions and light duy
1
W~ 01/07577 CA 02379723 2002-O1-17 pCT~S00/18854
detergents. A primary reason for the absence of these proteases in products
such as, for example,
soaps, gels, body washes, shampoos, and light duty dish detergents is due to
the problem of
human sensitization leading to undesirable immunogenic responses. It would
therefore be highly
advantageous to provide a personal care composition or light duty detergent
which provides the
cleansing properties of proteases without the provocation of an immunogenic
response.
Presently, immunogenic response to proteases may be minimized by immobilizing,
granulating, coating, or dissolving chemically modified proteases to avoid
their becoming
airborne. These methods, while addressing consumer exposure to airborne
proteases, still present
the risks associated with extended tissue contact with the finished
composition and worker
exposure to protease-containing dust or aerosol during manufacturing.
It has also been proposed that reduction in immunogenicity of a protease may
be
achieved by attaching polymers to the protease. See, e.~., U.S. Patent No.
4,179,337, Davis et al.,
issued December 18, 1979; U.S. Patent No. 5,856,451, Olsen et al., assigned to
Novo Nordisk,
issued January 5, 1999; WO 99/00489, Olsen et al., assigned to Novo Nordisk,
published January
7, 1999; WO 98/30682, Olsen et al., assigned to Novo Nordisk, published July
16, 1998; and WO
98/35026, Von Der Osten et al., published August 13, 1998. However, such
proposals have not
suggested the importance of attaching polymers to the amino acid regions of
the protease which
are responsible for the immune response (i.e., epitopes).
It has recently been discovered that the subtilisin protease comprises three
epitope
regions and that conjugation of one or more polymers, polypeptides, or other
groups should be
attached at one or more of these regions to effect significant reduction in
immunogenicity of the
protease. See, e.~., U.S. Patent Application Serial No. 09/088,912, Weisgerber
et al., assigned to
The Procter & Gamble Co., filed June 2, 1998.
The present inventors have discovered that steric protection near one or more
of the
epitope regions of the protease is an alternative mechanism to prevent or
impede presentation of
an epitope and decrease the immunogenicity of the protease. Accordingly, the
present inventors
herein provide modified subtilisins wherein the modification is at a region in
steric proximity to
one or more of the epitope regions. The present inventors have therefore
discovered subtilisin
proteases which evoke a decreased immunogenic response yet maintain their
activity as an
efficient and active protease. Accordingly, the present protease conjugates
are suitable for use in
several types of compositions including, but not limited to, laundry, dish,
hard surface, skin care,
hair care, beauty care, oral care, and contact lens compositions.
SUMMARY OF THE INVENTION
2
W~ X1/07$77 CA 02379723 2002-O1-17 pCT~S00/18854
The present invention relates to protease conjugates comprising a protease
moiety and
one or more addition moieties, wherein each addition moiety is covalently
attached to an epitope
protection position of the protease moiety, wherein:
(a) the epitope protection positions for the first epitope region are selected
from 1, 2, 3, 4, 5,
6, 7, 12, 17, 36, 40, 41, 43, 44, 45, 67, 86, 87, 89, 206, 209, 210, 212, 213,
214, 215, and
216 corresponding to subtilisin BPN ;
(b) the epitope protection positions for the second epitope region are
selected from 25, 26,
27, 46, 47, 48, 49, 50, 51, 52, 53, 54, 91, 99, 100, 101, 102, 127, 128, 129,
130, 131, 132,
133, 134, 136, 137, 138, 140, 141, 144, and 145 corresponding to subtilisin
BPN'; and
(c) the epitope protection positions for the third epitope region are selected
from 9, 10, 22,
23. 24, 62, 63, 143, 146, 154, 155, 156, 157, 172, 173, 187, 189, 195, 197,
203, 204, 253,
254, 256, 265, 267, 269, 271, 272, and 275 corresponding to subtilisin BPN;
and wherein the addition moieties each, independently, have the structure:
R~
2
wherein X is selected from nil and a linking moiety; R1 is selected from nil,
a first polypeptide,
and a first polymer; and RZ is selected from nil, a second polypeptide, and a
second polymer;
wherein at least one of X, R,, and R~ is not nil.
The protease conjugates of the present invention have decreased immunogenicity
relative
to the parent protease. Accordingly, such protease conjugates are suitable for
use in several types
of compositions including, but not limited to, laundry, dish, hard surface,
skin care, hair care,
beauty care, oral care, and contact lens compositions.
DETAILED DESCRIPTION OF THE INVENTION
The essential components of the present invention are herein described below.
Also
included are non-limiting descriptions of various optional and preferred
components useful in
embodiments of the present invention.
The present invention can comprise, consist of, or consist essentially of any
of the
required or optional components and / or limitations described herein.
All percentages and ratios are calculated by weight unless otherwise
indicated. All
percentages are calculated based on the total composition unless otherwise
indicated.
All component or composition levels are in reference to the active level of
that
component or composition, and are exclusive of impurities, for example,
residual solvents or by-
products, which may be present in commercially available sources.
3
W~ ~l/~7577 CA 02379723 2002-O1-17 pCT~7S00/18854
All documents referred to herein, including all patents, patent applications,
and
publications, are hereby incorporated by reference in their entirety.
Referred to herein are trade names for materials including, but not limited
to, enzymes.
The inventors herein do not intend to be limited by materials under a certain
trade name.
Equivalent materials (e.g., those obtained from a different source under a
different name or
catalog (reference) number) to those referenced by trade name may be
substituted and utilized in
the protease conjugates and compositions herein.
As used herein, abbreviations will be used to describe amino acids. Table I
provides a
list of abbreviations used herein:
Table I
Amino Acid Three-letter AbbreviationOne-letter Abbreviation
Alanine Ala A
Ar mine Ar R
As ara ine Asn N
As artic Acid As D
Cysteine C s C
Glutamine Gln Q
Glutamic Acid Glu E
Gl cine Gly G
Histidine His H
Isoleucine Ile I
Leucine Leu L
L sine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
T to han T W
T osine T Y
Valine Val V
4
VV~ 01/07$77 CA 02379723 2002-O1-17
PCT/LJS00/188$4
Definitions
As used herein, the term "mutation" refers to an alteration in a gene sequence
and / or an
amino acid sequence produced by those gene sequences. Mutations include
deletions,
substitutions, and additions of amino acid residues to the wild-type protein
sequence.
As used herein, the term "parent" refers to a protein (wild-type or variant)
which is
utilized for further modification to form a protease conjugate herein.
As used herein, the term "wild-type" refers to a protein, for example a
protease or other
enzyme, produced by unmutated organisms.
As used herein, the term "variant" means a protein having an amino acid
sequence which
differs from that of the corresponding wild-type protein.
As used herein, all polymer molecular weights are expressed as weight average
molecular
weights.
As referred to herein, while the conjugates of the present invention are not
limited to
those comprising subtilisin BPN' and variants thereof, all amino acid
numbering is with reference
to the amino acid sequence for subtilisin BPN' which is represented by SEQ m
NO:l. The amino
acid sequence for subtilisin BPN' is further described by Wells et al.,
Nucleic Acids Research,
Vol. II, pp. 7911 - 7925 (1983).
Protease Contu~ates of the Present Invention
The protease conjugates of the present invention are compounds which comprise
a
protease moiety and one or more addition moieties, wherein the protease moiety
and the addition
moieties are connected via covalent attachment (i. e., covalent bonding).
Protease Moieties
The protease moieties herein are subtilisin-like proteases, either wild-type
or variants
thereof. As used herein, the term "subtilisin-like protease" means a protease
which has at least
50%, and preferably 80%, amino acid sequence identity with the sequences of
subtilisin BPN'.
Wild-type subtilisin-like proteases are produced by, for example, Bacillus
alcalophilus, Bacillus
amyloliquefaciens, Bacillus amylosaccharicus, Bacillus licheniformis, Bacillus
lentus, and
Bacillus subtilis microorganisms. A discussion relating to subtilisin-like
serine proteases and
their homologies may be found in Siezen et al., "Homology Modelling and
Protein Engineering
Strategy of Subtilases, the Family of Subtilisin-Like Serine Proteases",
Protein Engineering. Vol.
4, No. 7, pp. 719 - 737 (1991).
Preferred protease moieties for use herein include, for example, those
obtained from
Bacillus amyloliquefaciens, Bacillus licheniformis, and Bacillus subtilis,
subtilisin BPN,
CA 02379723 2002-O1-17
WO 01/07577 PCT/iJS00/18854
subtilisin BPN', subtilisin Carlsberg, subtilisin DY, subtilisin 309,
proteinase K, and thermitase,
including A/S Alcalase~ (commercially available from Novo Industries,
Copenhagen, Denmark),
Esperase~ (Novo Industries), Savinase~ (Novo Industries), Maxatase~
(commercially available
from Genencor International Inc.), Maxacal~ (Genencor International Inc.),
Maxapem 15~
(Genencor International Inc.), and variants of the foregoing. Especially
preferred protease
moieties for use herein include those obtained from Bacillus amyloliquefaciens
and variants
thereof. The most preferred protease moieties herein are subtilisin BPN' and
variants thereof.
Especially preferred variants of subtilisin BPN', hereinafter referred to as
"Protease A",
for use as parent amino acid sequences herein are disclosed in U.S. Patent No.
5,030,378,
Vene as, issued July 9, 1991, as characterized by the subtilisin BPN' amino
acid sequence with
the following mutations:
(a) Gly at position 166 is substituted with an amino acid residue selected
from Asn, Ser,
Lys, Arg, His, Gln, Ala and Glu; Gly at position 169 is substituted with Ser;
and Met
at position 222 is substituted with an amino acid residue selected from Gln,
Phe, His,
Asn, Glu, Ala and Thr; or
(b) Gly at position 160 is substituted with Ala, and Met at position 222 is
substituted
with Ala.
Additionally preferred variants of subtilisin BPN', hereinafter referred to as
"Protease B",
for use as parent amino acid sequences herein are disclosed in EP 251,446,
assigned to Genencor
International. Inc., published January 7, 1988, as characterized by the wild-
type subtilisin BPN'
amino acid sequence with mutations at one or more of the following positions:
Tyr2l, Thr22,
Ser24, Asp36, A1a45, A1a48, Ser49, Met50, His67, Ser87, Lys94, Va195, G1y97,
Ser101, G1y102,
GIy103, I1e107, G1y110, Met 124, GIyl27, GIy128, Pro129, Leu135, Lys170,
Tyr171, Pro172,
Asp197, Metl99, Ser204, Lys213, Tyr214, G1y215, and Ser221; or two or more of
the positions
listed above combined with one or more mutations at positions selected from
Asp32, Ser33,
Tyr104, A1a152, Asn155, G1u156, GIy166, Glyl69, Phel89, Tyr217, and Met222.
Other preferred subtilisin BPN' variants for use herein are hereinafter
referred to as
"Protease C", and are described in WO 95/10615, assigned to Genencor
International Inc.,
published April 20, 1995, as characterized by the wild-type subtilisin BPN'
amino acid sequence
with a mutation to position Asn76, in combination with mutations in one or
more other positions
selected from Asp99, Ser101, G1n103, Tyr104, Ser105, I1e107, Asn109, Asnl23,
Leul26,
GIy127, G1y128, Leu135, G1u156, GIy166, G1u195, Aspl97, Ser204, G1n206,
Pro210, A1a216,
Tyr217, Asn218, Met222, Ser260, Lys265, and A1a274.
6
W~ 01/07$77 CA 02379723 2002-O1-17 pCT~S00/18854
Other preferred subtilisin BPN' variants for use herein, hereinafter referred
to as
"Protease D", are described in U.S. Patent No. 4,760,025, Estell et al.,
issued July 26, 1988, as
characterized by the wild-type subtilisin BPN' amino acid sequence with
mutations to one or
more amino acid positions selected from the group consisting of Asp32, Ser33,
His64, Tyr104,
Asn 1 S 5, Glu 15 6, Gly 166, Gly 169, Phe 189, Tyr217, and Met222.
The more preferred protease moieties herein are selected from the group
consisting of
subtilisin BPN', Protease A, Protease B, Protease C, and Protease D, with
Protease D being the
most preferred.
Without intending to be limited by theory, the protease moieties herein have
three
epitope regions: a first epitope region, a second epitope region, and a third
epitope region. The
first epitope region occurs at positions 70 - 84 corresponding to subtilisin
BPN'; the second
epitope region occurs at positions 103 - 126 corresponding to subtilisin BPN';
and the third
epitope region occurs at positions 220 - 246 corresponding to subtilisin BPN'.
See, e.~., U.S.
Patent Application Serial No. 09/088,912, Weisgerber et al., assigned to The
Procter & Gamble
Co., filed June 2, 1998; copending U.S. Provisional Patent Application Serial
No. 60/144,991,
Rubingh et al., "Serine Protease Variants Having Amino Acid Substitutions and
Deletions in
Epitope Regions" filed July 22, 1999; and copending U.S. Provisional Patent
Application Serial
No. 60/144,980, Sikorski et al., "Serine Protease Variants Having Amino Acid
Substitutions in
Epitope Regions" filed July 22, 1999.
The present inventors have surprisingly discovered epitope protection
positions which
are in steric proximity to at least one of the foregoing epitope regions. It
has further been
discovered that these epitopes are protected from hydrolysis, and thus
exposure of epitopes, by
covalently attaching one or more addition moieties to an amino acid of the
protease moiety at an
epitope protection position.
The epitope protection positions which are appropriate for covalent
modification with an
addition moiety depend upon which epitope one desires to protect. Most
preferably, at least one
addition moiety is covalently attached to an epitope protection position for
the first epitope
region.
It has been discovered that the epitope protection positions for the first
epitope region are
1, 2, 3, 4, S, 6, 7, 12, 17, 36, 40, 41, 43, 44, 45, 67, 86, 87, 89, 206, 209,
210, 212, 213, 214, 215,
and 216 corresponding to subtilisin BPN'. Preferably, the epitope protection
positions for the
first epitope region are 1, 2, 3, 4, 5, 6, 7, 12, 17, 40, 41, 43, 67, 86, 87,
89, 206, 209, 214, and 215
corresponding to subtilisin BPN'. Most preferably, the epitope protection
positions for the first
7
CA 02379723 2002-O1-17
WO 01/07577 PCT/i1S00/18854
epitope region are l, 2, 3, 4, 5, 17, 40, 41, 43, 67, 86, 87, and 214
corresponding to subtilisin
BPN'.
It has further been discovered that the epitope protection positions for the
second epitope
region are 25, 26, 27, 46, 47, 48, 49, 50, 51, 52, 53, 54, 91, 99, 100, 101,
102, 127, 128, 129, 130,
131, 132, 133, 134, 136, 137, 138, 140, 141, 144, and 145 corresponding to
subtilisin BPN'.
Preferably, the epitope protection positions for the second epitope region are
27, 47, 48, 50, 52,
102, 127, 128, 130, 131, 132, 134, 138, and 141 corresponding to subtilisin
BPN'.
It has further been discovered that the epitope protection positions for the
third epitope
region are selected from the group consisting of 9, 10, 22, 23, 24, 62, 63,
143, 146, 154, 155, 156,
157, 172, 173, 187, 189, 195, 197, 203, 204, 253, 254, 256, 265, 267, 269,
271, 272, and 275
corresponding to subtilisin BPN'. Preferably, the epitope protection positions
for the second
epitope region are 22, 23, 24, 143, 146, 155, 173, 189, 197, 203, 204, 253,
254, 265, and 275
corresponding to subtilisin BPN'.
In a preferred embodiment of the present invention, the protease moiety
comprises a
modified sequence of a parent amino acid sequence. The parent amino acid
sequence may be any
of the above proteases described above, with the same preferred limitations as
described above.
In this embodiment, the parent amino acid sequence is substituted at one or
more of the parent
amino acid residues with a substituting amino acid to produce a protease
moiety suitable for
attachment with one or more of the present addition moieties. In accordance
with the present
invention, the substitution should be made at one or more of the epitope
protection positions.
The epitope protection positions, and preferred limitations thereof, are
described above.
In order to best achieve selective attachment at one or more of the epitope
protection
positions of one or more addition moieties to the protease moiety, the
substitution should be with
a substituting amino acid which does not occur in (is unique to) the parent
amino acid sequence.
In this respect, any substituting amino acid which is unique to the parent
amino acid sequence
may be utilized. For example, because a cysteine residue does not occur in the
wild-type amino
acid sequence for subtilisin BPN', a substitution of subtilisin BPN' with one
or more cysteine
residues at one or more of the epitope protection positions is suitable for
the present invention.
Wherein a cysteine residue occurs at a position other than an epitope
protection position of the
parent amino acid sequence, it is preferable to substitute another amino acid
residue for in each of
those positions to enable selective coupling with one or more addition
moieties at an epitope
protection position. Cysteine is the most preferred substituting amino acid
for substitution at one
or more of the epitope protection positions.
8
VV~ 01/07577 CA 02379723 2002-O1-17 pCT~S00/18854
Other preferred substituting amino acids include lysine. Wherein the
substituting amino
acid is lysine, it is preferred to mutate lysine residues which occur at
positions other than an
epitope protection position of the parent amino acid sequence to another amino
acid residue such
that functionalization of one or more of the lysine residues at an epitope
protection position is
selective. For example, a lysine residue occurs at position 43 of subtilisin
BPN' which is an
epitope protection position as defined herein. Site-selective mutation of all
other lysine residues
occurring in the subtilisin BPN' sequence may be performed followed by
selective
functionalization of the lysine residue at position 43 with an addition
moiety. Alternatively,
amino acid residues at any of the epitope protection positions may be mutated
to lysine (for
example) followed by selective functionalization at those positions by an
addition moiety.
Addition Moieties
The protease conjugates of the present invention comprise one or more addition
moieties
wherein each of the addition moieties is covalently attached to one of the
amino acid residues at
an epitope protection position as described herein. The addition moiety may be
any chemical
structure. Preferably, the addition moiety sterically hinders the epitope
protection position to
which it is attached, or any other epitope protection position as defined
herein. Non-limiting
examples of addition moieties include organic molecules including, but not
limited to, molecules
having a molecular weight of less than about 1600, preferably less than about
800, more
preferably less than about 400, and most preferably less than about 300;
polypeptides; and
polymers. As used herein, the term "polypeptide" means a molecule comprising
two or more
amino acid residues. As used herein, the term "polymer" means any molecule
which comprises
two or more identical (preferably five or more identical) monomer units.
Preferably, the addition moiety has the structure:
Rl~ X-
R~
2
wherein X is selected from nil and a linking moiety; R, is selected from the
group consisting of
nil, a first polypeptide, and a first polymer; and Rz is selected from the
group consisting of nil, a
second polypeptide, and a second polymer, wherein at least one of X, R,, and
RZ is not nil.
Preferably, the protease conjugate comprises from 1 to about 15, more
preferably from
about 2 to about 10, and most preferably from about 1 to about 5 addition
moieties.
Wherein R, and R~ are each, independently, polypeptide moieties or polymer
moieties, R,
and RZ may be identical or different. Preferably, wherein Rl is a polypeptide
moiety, RZ is
selected from nil and a polypeptide moiety, and is most preferably nil. Most
preferably, wherein
9
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
R, is a polypeptide moiety, RZ is selected from nil and an identical
polypeptide moiety, and is
most preferably nil. Preferably, wherein RI is a polymer moiety, R~ is
selected from nil and a
polymer moiety. Most preferably, wherein Rl is a polymer moiety, Rz is
selected from nil and an
identical polymer moiety. Wherein at least one of R, and RZ are respectively,
the first polymer
and the second polymer, then X is preferably not nil.
Polypeptide Moieties
The polypeptide moieties described herein include those comprising two or more
amino
acid residues. Preferred polypeptide moieties are selected from proteins,
including enzymes.
Preferred enzymes include proteases, cellulases, lipases, amylases,
peroxidases,
microperoxidases, hemicellulases, xylanases, phospholipases, esterases,
cutinases, pectinases,
keratinases, reductases (including, for example, NADH reductase), oxidases,
phenoloxidases,
lipoxygenases, ligninases, pullulanases, tannases, pentosanases, malanases, (3-
glucanases,
arabinosidases, hyaluronidase, chondroitinase, laccases, transferases,
isomerases (including, for
example, glucose isomerase and xylose isomerase), lyases, ligases,
synthetases, and fruit-based
enzymes (including, for example, papain). More preferred enzymes for use as
polypeptide
moieties include proteases, cellulases, amylases, lipases, and fruit-based
enzymes, with proteases
being even more preferred.
Examples of lipases for use as a polypeptide moiety include those derived from
the
following microorganisms: Humicola, Pseudonomas, Fusarium, Mucor,
Chromobacterium,
Aspergillus, Candida, Geotricum, Penicillium, Rhizopus, and Bacillus.
Examples of commercial lipases include Lipolase~, Lipolase Ultra , Lipozyme~,
Palatase~. Novozym435~, and Lecitase (all of which are commercially available
from Novo
Nordisk, Copenhagen, Denmark), Lumafast~ (commercially available from
Genencor, Int.,
Rochester, NY), and Lipomax~ (Genencor, Int.).
Examples of proteases for use as the polypeptide moiety include serine
proteases,
chymotrypsin, and elastase-type enzymes. The most preferred proteases for use
as a polypeptide
moiety include serine proteases, as were defined herein above in the
discussion of "protease
moieties".
Most preferably, wherein the polypeptide moiety is a serine protease, the
polypeptide
moiety carries, independently, the definition of a protease moiety as
described herein above.
Preferably, as described above, the polypeptide moiety has a modified amino
acid sequence of a
parent amino acid sequence wherein the modification is in one or more of the
epitope protection
positions as described herein above (which parent amino acid sequence may be
referred to as a
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
"second" parent amino acid sequence). In this instance, one of the linking
moiety (wherein the
linking moiety is not nil) or the protease moiety (wherein the linking moiety
is nil) is covalently
attached to the polypeptide moiety through one of the substituting amino acids
present in one of
the epitope protection positions of the polypeptide moiety. Wherein the
polypeptide moiety is a
serine protease, the same preferred groupings of epitope protection positions
apply as are
described herein above for protease moieties and their corresponding parent
amino acid
sequences.
Most preferably, wherein the polypeptide moiety is a serine protease, the
polypeptide
moiety and the protease moiety are equivalent moieties. In this instance, the
polypeptide moiety
and the protease moiety are most preferably attached through a disulfide
bridge, wherein X is nil,
and most preferably, Rz is nil.
Polymer Moieties
The addition moieties herein may comprise a polymer moiety. As used herein,
the term
polymer moiety means any molecule which comprises two or more identical
(preferably five or
more identical) monomer units. Examples of suitable polymer moieties include
polyalkylene
oxides, polyalcohols, polyvinyl alcohols, polycarboxylates,
polyvinylpyrrolidones, celluloses,
dextrans, starches, glycogen, agaroses, guar gum, pullulan, inulin, xanthan
gum, carrageenan,
pectin, alginic acid hydrosylates, and hydrosylates of chitosan. Preferred
polyalkylene oxides
include polyethylene glycols, methoxypolyethylene glycols, and polypropylene
glycols.
Preferred dextrans include carboxyrnethyldextrans. Preferred celluloses
include methylcellulose,
carboxymethylcellulose, ethylcellulose, hydroxyethyl cellulose, carboxyethyl
cellulose, and
hydroxypropylcellulose. Preferred starches include hydroxyethyl starches and
hydroxypropyl
starches. The more preferred polymers are polyalkylene oxides. The most
preferred polymer
moiety is polyethylene glycol.
Wherein R~ and RZ are each, independently, polymer moieties, R, and Rz
preferably has a
collective molecular weight (i.e., molecular weight of R~ plus molecular
weight of R~) of from
about 0.2 kD (kilodaltons) to about 40kD, more preferably from about 0.5 kD to
about 40 kD,
even more preferably from about 0.~ kD to about 20 kD, and most preferably
from about 1 kD to
about 10 kD.
Wherein R, and R~ are each polymer moieties, R, and RZ each, independently,
preferably
have a molecular weight of about 0.1 kD to about 20kD, more preferably from
about 0.25 kD to
about 20 kD, even more preferably from about 0.5 kD to about 10 kD, and most
preferably from
about 0.5 kD to about 5 kD.
11
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
Wherein R~ and RZ are each polymer moieties, the ratio of the molecular
weights of R1 to
R2 preferably ranges from about 1:10 to about 10:1, more preferably from about
1:5 to about 5:1,
and most preferably from about 1:3 to about 3:1.
Wherein Rl is a polymer moiety and RZ is nil, R, preferably has a molecular
weight of
from about 0.1 kD to about 40kD, more preferably about 0.5 kD to about 40 kD,
even more
preferably from about 0.5 kD to about 20 kD, and most preferably from about 1
kD to about 10
kD.
Linking Moieties
As used herein, X may be nil or a linking moiety which is optionally
covalently attached
to one or more polypeptide moieties or one or more polymer moieties, or both,
and is also
covalently attached to an amino acid residue at one of the epitope protection
positions of the
protease moiety. The linking moiety may be, generally, any small molecule,
i.e., a molecule
having a molecular weight of less than about 1600, preferably less than about
800, more
preferably less than about 400, and most preferably less than about 300. The
most preferred
linking moieties include those capable of being covalently bound to a cysteine
residue or a lysine
residue, most preferably a cysteine residue.
Examples of linking moieties and related chemistry are disclosed in U.S.
Patent No.
5,446,090, Harns, issued August 29, 1995; U.S. Patent No. 5,171,264, Merrill,
issued December
15, 1992; U.S. Patent No. 5,162,430, Rhee et al., issued November 10, 1992;
U.S. Patent No.
5,153,265, Shadle et al., issued October 6, 1992; U.S. Patent No. 5,122,614,
Zali s , issued
June 16, 1992; Goodson et al., "Site-Directed Pegylation of Recombinant
Interleukin-2 at its
Glycosylation Site", Biotechnology, Vol. 8, No. 4, pp. 343 - 346 (1990);
Ko_a~n, "The Synthesis
of Substituted Methoxy-Polyethylene glycol) Derivatives Suitable for Selective
Protein
Modification", Synthetic Communications, Vol. 22, pp. 2417 - 2424 (1992); and
Ishii et al.,
"Effects of the State of the Succinimido-Ring on the Fluorescence and
Structural Properties of
Pyrene Maleimide-Labeled aa-Tropomyosin", Biophysical Journal, Vol. 50, pp. 75
- 80 (1986).
The most preferred linking moiety is substituted (for example, alkyl) or
unsubstituted
succinimide.
As further examples, the following non-limiting reagents may be utilized to
form the
linking moiety: N-[alpha-maleimidoacetoxy]succinimide ester; N-5-azido-2-
nitrobenzoyloxysuccinimide; bismaleimidohexane; N-[beta-
maleimidopropyloxy]succinimide
ester; bis[2-(succinimidyloxycarbonyloxy)-ethyl]sulfone;
bis[sulfosuccinimidyl]suberate; 1,5-
difluoro-2,4-dintrobenzene; dimethlyadipimate ~ 2 HCI; dimethylpimelimidate ~
2 HCI;
12
W~ O1/~7577 CA 02379723 2002-O1-17
PCT/US00/18854
dimethylsuberimidate ~ 2 HCI; disuccinimidyl glutarate; disuccinimidyl
suberate; m-
maleimidobenzoyl-N-hydroxysuccinimide ester; N-hydroxysuccinimidyl-4-
azidosalicylic acid; N-
succinimidyl-6-[4'-azido-2'-nitrophenylamino]hexanoate; N-hydroxysuccinimidyl
2,3-
dibromopropionate; succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-
carboxylate;
succinimidyl 4-(p-maleimidophenyl)-butyrate; succinimidyl-6-[(beta-
maleimidopropionamido)hexanoate]; bis[2-(sulfosuccinimidyloxycarbonyloxy)-
ethyl]sulfone; N-
[gamma-maleimidobutyryloxy]sulfosuccinimide ester; N-hydroxysulfosuccinimidyl-
4-
azidobenzoate; N-[kappa-maleimidoundecanoyloxy]sulfosuccinimide ester; m-
maleimidobenzoyl-N-hydroxysulfosuccinimide ester; sulfosuccinimidyl[4-
azidosalicylamido]hexanoate; sulfosuccinimidyl 7-azido-4-methylcoumarin-3-
acetate;
sulfosuccinimidyl 6-[4'-azido-2'-nitrophenylamino]hexanoate; sulfosuccinimidyl
4-[p-
azidophenyl]butyrate; sulfosuccinimidyl[4-iodoacetyl]aminobenzoate;
sulfosuccinimidyl 4-[N-
maleimidomethyl]cyclohexane-1-carboxylate; and sulfosuccinimidyl 4-(p-
maleimidophenyl)-
butyrate. Each of these reagents is commercially available from Pierce
Chemical Co., Rockford,
IL.
Optional Moieties
The protease conjugate may additionally comprise one or more other chemical
structures,
including (for example) one or more small molecules, polypeptides, and / or
polymers attached to
other residues of the protease not herein exemplified or even at an epitope
protection position not
bearing an addition moiety (herein referred to as "supplementary moieties").
Supplementary
moieties may include polypeptide moieties, polymer moieties, and linking
moieties as described
herein above. Additionally, for example, one or more polymers (most preferably
polyethylene
glycol) having a molecular weight of from about 100 Da to about 5000 Da,
preferably from about
100 Da to about 2000 Da, more preferably from about 100 Da to about 1000 Da,
still more
preferably from about 100 Da to about 750 Da, and most preferably about 300 Da
may be
covalently attached to the protease moiety herein at residues other than those
exemplified herein.
Such polymer moieties may be attached directly to the protease moiety herein,
at any location of
the protease moiety, using techniques as described herein and as well-known in
the art (including
through a linking moiety as described herein). Non-limiting examples of
polymer conjugation of
this optional type is set forth in WO 99/00849, Olsen et al., Novo Nordisk
A/S, published January
7, 1999.
Method of Making
13
W~ 01/07577 CA 02379723 2002-O1-17
PCT/US00/18854
The protease moieties having a substitution in one or more of the epitope
protection
positions (or any other location of the moiety) are prepared by mutating the
nucleotide sequences
that code for a parent amino acid sequence. Such methods are well-known in the
art; a non-
limiting example of one such method is set forth below:
A phagemid (pSS-5) containing the wild-type subtilisin BPN' gene (Mitchison,
C. and
J.A. Wells, "Protein Engineering of Disulfide Bonds in Subtilisin BPN"',
Biochemistry, Vol. 28,
pp. 4807 - 4815 (1989) is transformed into Escherichia coli dut- ung- strain
CJ236 and a single
stranded uracil-containing DNA template is produced using the VCSM13 helper
phage (Kunkel
et al., "Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic
Selection", Methods in
Enzymology, Vol 154, pp. 367 - 382 (1987), as modified by Yuckenber- eg t al.,
"Site-Directed in
vitro Mutagenesis Using Uracil-Containing DNA and Phagemid Vectors", Directed
Muta~enesis
- A Practical Approach, McPherson, M. J. ed., pp. 27 - 48 (1991). Primer site-
directed
mutagenesis modified from the method disclosed in Zoller, M. J., and M. Smith,
"Oligonucleotide - Directed Mutagenesis Using M13 - Derived Vectors: An
Efficient and
General Procedure for the Production of Point Mutations in any Fragment of
DNA", Nucleic
Acids Research, Vol. 10, pp. 6487 - 6500 (1982) is used to produce all mutants
(essentially as
presented by Yuckenberg et al., supra).
Oligonucleotides are made using a 380B DNA synthesizer (Applied Biosystems
Inc.).
Mutagenesis reaction products are transformed into Escherichia coli strain
MM294 (American
Type Culture Collection E. coli 33625). All mutations are confirmed by DNA
sequencing and
the isolated DNA is transformed into the Bacillus subtilis expression strain
PG632 (Saunders et
al., "Optimization of the Signal-Sequence Cleavage Site for Secretion from
Bacillus subtilis of a
34-Amino Acid Fragment of Human Parathyroid Hormone", Gene, Vol. 102, pp. 277 -
282
(1991) and Yang et al., "Cloning of the Neutral Protease Gene of Bacillus
subtilis and the Use of
the Cloned Gene to Create an in vitro - Derived Deletion Mutation", Journal of
Bacteriology,
Vol. 160, pp. 15 - 21 (1984).
Fermentation is as follows. Bacillus subtilis cells (PG632) containing the
protease of
interest are grown to mid-log phase in one liter of LB broth containing 10 g/L
glucose, and
inoculated into a Biostat C fermentor (Braun Biotech, Inc., Allentown, PA) in
a total volume of 9
liters. The fermentation medium contains yeast extract, casein hydrosylate,
soluble - partially
hydrolyzed starch (Maltrin M-250), antifoam, buffers, and trace minerals (see
"Biology of
Bacilli: Applications to Industry", Doi, R. H. and M. McGloughlin, eds.
(1992)). The broth is
kept at a constant pH of 7.5 during the fermentation run. Kanamycin (50 pg/mL)
is added for
14
W~ 01/07577 CA 02379723 2002-O1-17 pCT/US00/18854
antibiotic selection of the mutagenized plasmid. The cells are grown for 18
hours at 37 °C to an
A~ of about 60 and the product harvested.
The fermentation broth is taken through the following steps to obtain pure
protease. The
broth is cleared of Bacillus subtilis cells by tangential flow against a 0.16
p.m membrane. The
cell-free broth is then concentrated by ultrafiltration with a 8,000 molecular
weight cut-off
membrane. The pH is adjusted to 5.5 with concentrated MES buffer (2-(N-
morpholino)ethanesulfonic acid). The protease is further purified by canon
exchange
chromatography with S-sepharose and elution with NaCI gradients. See Scopes,
R. K., "Protein
Purification Principles and Practice", Springer-Verlag, New York (1984)
ApNA assay (DelMar et al., Analytical Biochemistry, Vol. 99, pp. 316 - 320
(1979)) is
used to determine the active protease concentration for fractions collected
during gradient
elution. This assay measures the rate at which p-nitroaniline is released as
the protease
hydrolyzes the soluble synthetic substrate, succinyl-alanine-alanine-proline-
phenylalanine p-
nitroaniline (sAAPF pNA). The rate of production of yellow color from the
hydrolysis reaction
is measured at 410 nm on a spectrophotometer and is proportional to the active
protease moiety
concentration. In addition, absorbance measurements at 280 nm are used to
determine the total
protein concentration. The active protease/total-protein ratio gives the
protease purity, and is
used to identify fractions to be pooled for the stock solution.
To avoid autolysis of the protease during storage, an equal weight of
propylene glycol is
added to the pooled fractions obtained from the chromatography column. Upon
completion of
the purification procedure the purity of the stock protease solution is
checked with SDS-PAGE
(sodium dodecyl sulfate polyacrylamide gel electrophoresis) and the absolute
enzyme
concentration is determined via an active site titration method using trypsin
inhibitor type II-T:
turkey egg white (Sigma Chemical Company, St. Louis, Missouri).
In preparation for use, the protease stock solution is eluted through a
Sephadex-G25
(Pharmacia, Piscataway, New Jersey) size exclusion column to remove the
propylene glycol and
exchange the buffer. The MES buffer in the enzyme stock solution is exchanged
for 0.01 M
KH~P04 solution, pH 5.5.
With the protease prepared it may be utilized for functionalization with one
or more
addition moieties to produce the protease conjugate. The precursor to the
addition moiety (the
precursor to the addition moiety reacts with the precursor to the protease
moiety to form the
protease conjugate which is comprised of the addition moiety and the protease
moiety) is
preferably activated to enhance reactivity with the precursor to the protease
moiety. Such
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
activation is well-lrnown in the art. Non-limiting examples of methods of
protease conjugate
preparation are provided below.
Example 1
O
H3C n ~ ~ O
O
--~ H3C~ n O
O
P SH
A protease comprising a cysteine residue at one of the epitope protection
positions is
coupled with a polymer moiety according to the above scheme using the
following method
(wherein "P" represents the protease moiety minus the thiol group resulting
from the cysteine
substitution and n is the number of repeating monomer units of the
polyethylene glycol (for
example, n = 77).
A variant of subtilisin BPN' with a substitution of leucine for tyrosine at
position 217 and
a substitution of cysteine for serine at position 3 is prepared. A
concentration of approximately 2
mg / mL in phosphate buffer (pH 5.5) of the variant is achieved. The pH is
then raised to 7.5
with dilute sodium hydroxide. The variant is mixed with the monomethyl
polyethylene glycol
maleimide at a 25:1 activated polymer to variant excess. After one hour of
mixing at ambient
temperature, the pH of the mixture is adjusted to 5.5 with dilute phosphoric
acid and filtered
through a molecular weight cut-off ultrafilter to remove excess polymer. The
concentrate
contains the purified protease conjugate.
16
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
Example 2
O
O O 0I -NH
H3C n (CHZ)a ~ O
O O~O NH~NH~NH N
H3C ~ ~ n ~ I IO
O
P SH
O
O O O' -NH
H3C n (CHZ)4 O O
~ ~ S
~O O O NH~NH~NH~N P
H3C ~ ~ I IO
O
A protease moiety comprising a cysteine residue at one of the epitope
protection
positions is coupled with a polymer moiety according to the above scheme using
the following
method (wherein "P" represents the protease moiety minus the thiol group
resulting from the
cysteine substitution and n is the number of repeating monomer units of each
polyethylene glycol
(e.g., n = 77)).
A variant of subtilisin BPN' with a substitution of leucine for tyrosine at
position 217 and
a substitution of cysteine for phenylalanine at position 17 is prepared. A
concentration of
approximately 2 mg / mL in phosphate buffer (pH 5.5) of the variant is
achieved. The pH is then
raised to 7.5 with dilute sodium hydroxide. The variant is mixed with the
dimethyl polyethylene
glycol maleimide at a 25:1 activated polymer to variant excess. After one hour
of mixing at
ambient temperature, the pH of the mixture is adjusted to 5.5 with dilute
phosphoric acid and
filtered through a molecular weight cut-off ultrafilter to remove excess
polymer. The concentrate
contains the purified protease conjugate.
17
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
Example 3
Succinimide-protected polymer is coupled selectively to lysine in one or more
of the
epitope protection positions (wherein "MPEG" and "PEGM" are equivalent and
represent
monomethyl polyethylene glycols and wherein "P" represents the protease moiety
minus the
lysine amine group shown):
O
O p
NH O~N~ HZN
MPEG
O
HN
~ PEGM
pH 8.5
O P
NH
MPEG~ NH
HN
~ PEGM
Example 4
Carbodiimide-protected polymer is coupled selectively to lysine in one or more
of the
epitope protection positions (wherein "MPEG" and "PEGM" are equivalent and
represent
monomethyl polyethylene glycols, "P" represents the protease moiety minus the
lysine amine
group shown, and X and X' are side chains comprising the carbodiimide moiety,
for example,
alkyls):
18
CA 02379723 2002-O1-17
WO 01/07577 PCT/iJS00/18854
X
O HN~ p
NH ~ HZN
MPEG~ O" N
I
X'
HN
~ PEGM
O P
NH
MPEG~ NH
HN
~ PEGM
Example 5
O R' O
I
, I
PSH+N pH7~0 SP
A protease moiety comprising a cysteine residue in one of the epitope
protection
positions is coupled with an alkyl maleimide using the following method
(wherein "P" represents
the protease moiety minus the thiol group resulting from the cysteine
substitution and "R" is an
alkyl group). In this example, R, and RZ are each nil and the linking moiety
is derived from the
alkyl maleimide.
A variant of subtilisin BPN' with a substitution of leucine for tyrosine at
position 217 and
a substitution of cysteine for serine at position 86 is prepared. A 20 mL
solution of the variant is
prepared at a concentration of approximately 1 mg / mL in 0.01 M KH~P04 buffer
(pH 7). To
this solution, an 1.5 equivalents of alkyl maleimide (for example, methyl
maleimide) is added to
the solution. The solution is gently mixed at ambient temperature for
approximately one hour.
The resulting protease conjugate is obtained from the solution by standard
methods.
19
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
Example 6
P
SH P S~S
P
2 Equivalents 1 Equivalent
A protease moiety comprising a cysteine residue at one of the epitope
protection
positions forms a dimer using the following method (wherein "P" represents the
protease moiety
minus the thiol group resulting from the cysteine substitution). In this
example, the protease
moiety and the polypeptide moiety are equivalent (and X is nil).
A variant of subtilisin BPN' with a substitution of leucine for tyrosine at
position 217 and
a substitution of cysteine for serine at position 214 is prepared. A 20 mL
solution of the variant
is prepared at a concentration of approximately 1 mg / mL in 0.01 M KHZP04
buffer (pH 8.6).
Oxygen is gently bubbled through the solution at ambient temperature for
approximately one
hour to form the desired protease conjugate dimer. The resulting protease
conjugate is obtained
from the solution by standard methods.
Analytical Methods
The present protease conjugates may be tested for enzymatic activity and
immunogenic
response using the following methods, both of which are known to one skilled
in the art. Other
methods well-known in the art may alternatively be used.
Protease Coniu~ate Activity
The protease activity of a protease conjugate of the present invention may be
assayed by
methods which are well-known in the art. Two such methods are set forth herein
below:
Skin Flake Activity Method
Using Scotch~ #37506 tape, human skin flakes are stripped from the legs of a
subject
repeatedly until the tape is substantially opaque with flakes. The tape is
then cut into 1 inch by 1
inch squares and set aside. In a 10 mm by 35 mm petri dish, 2 mL of 0.75 mg /
mL of a control
enzyme (for example, subtilisin BPN') or the protease conjugate to be tested
is added in 0.01 M
KH~P04 pH 5.5 buffer. To this solution 1 mL of 2.5% sodium laurate pH 8.6
solution is added.
The solution is gently mixed on a platform shaker. The previously prepared
tape square is soaked
in the solution (flake side up) for ten minutes continuing gentle mixing. The
tape square is then
rinsed gently in tap water for fifteen seconds. Stevenel Blue Stain (3 mL,
commercially available
from Sigma Chemical Co., St. Louis, MO) is pipetted into a clean petri dish.
The rinsed tape
WO X1/07577 CA 02379723 2002-O1-17 pCT~S00/18854
square is placed into the stain for three minutes (flake side up) with gentle
mixing. The tape
square is removed from the stain and rinsed consecutively in two beakers of
300 mL distilled
water, for fifteen seconds per rinse. The tape square is allowed to air-dry.
The color intensity
between the tape square obtained from the control enzyme and the tape square
obtained from the
protease conjugate is compared visually or by using a chromameter. Relative to
the control
enzyme tape square, a protease conjugate tape square showing less color
intensity is indicative of
a protease conjugate having higher activity.
Dyed Collagen Activity Method
Combine 50 mL of 0.1 M tris buffer (tris-hydroxymethyl-aminomethane)
containing 0.01
M CaCh to give pH 8.6, and 0.5 g azocoll (azo dye impregnated collagen,
commercially available
from Sigma Chemical Co., St. Louis, MO). Incubate this mixture at 25 °C
while gently mixing
with a platform shaker. Filter 2 mL of the mixture through a 0.2 micron
syringe filter and read
absorbance of the mixture at 520 nm to zero a spectrophotometer. Add 1 ppm of
a control
enzyme (for example, subtilisin BPN') or the protease conjugate to be tested
to the remaining 48
mL of tris / azocoll mixture. Filter 2 mL of the control / protease conjugate
containing solution
through a 0.2 micron syringe filter every two minutes for a total of ten
minutes. For each filtered
sample, read the absorbance immediately at 520 nm. Plot the results against
time. The slopes of
the control and the test conjugate are indicative of relative activities of
the samples. A higher
slope is indicative of a higher activity. The test protease conjugate activity
(slope) may be
expressed as a percent of the control activity (slope).
Mouse Intranasal Test for Immuno~yenicity
The immunogenic potential of the protease conjugates of the present invention
may be
determined using a methods lrnown in the art or by the Mouse Intranasal Test
for Immunogenicity
presented herein below. This test is similar to the assays described in
Robinson et al., "Specific
Antibody Responses to Subtilisin Carlsberg (Alcalase) in Mice: Development of
an Intranasal
Exposure Model", Fundamental and Applied Toxicology, Vol. 34, pp. 15 - 24
(1996) and
Robinson et al., "Use of the Mouse Intranasal Test (MINT) to Determine the
Allergenic Potency
of Detergent Enzymes: Comparison to the Guinea Pig Intratracheal (GPIT) Test",
Toxicological
Science, Vol. 43, pp. 39 - 46 (1998), both of which assays may be utilized in
place of the test set
forth herein below.
Female BDF 1 mice (Charles River Laboratories, Portage, MI) weighing from
about 18 to
about 20 grams are utilized in the test. The mice are quarantined one week
prior to dosing. The
mice are housed in cages with wood chip bedding in rooms controlled for
humidity (30 - 70%),
21
W~ 01/07$77 CA 02379723 2002-O1-17
PCT/US00/18854
temperature (67 - 77 °F) and 12 hour light and dark cycles. The mice
are fed Purina mouse
chow (Purina Mills, Richmond, IN) and water ad libitum.
The potential antigen to be tested (either subtilisin BPN' as positive control
or a protease
conjugate of the present invention) is dosed to a group of five mice. Prior to
dosing, each mouse
is anesthetized by an intraperitoneal (i.p.) injection of a mixture of Ketaset
(88.8 mg/kg) and
Rompun (6.67 mg/kg). The anesthetized animal is held in the palm of the hand,
back down, and
dosed intranasally with 5 p.L protease in buffer solution (0.01 M KHZP04, pH
5.5). While each
group receives the same dosage, various dosages may be tested. Dosing
solutions are gently
placed on the outside of each nostril and inhaled by the mouse. Dosing is
repeated on days 3, 10,
17, and 24.
Serum samples are collected on day 29. Enzyme-specific IgGl antibody in mouse
serum
is measured by an antigen capture ELISA method. Immunogenicities of the
protease conjugate
may be compared against those of subtilisin BPN' using standard EDSO values.
Compositions of the Present Invention
The protease conjugates herein can be used in any application in which is
suitable for the
respective parent protease. One such example includes cleaning compositions.
Because of the
desirable reduced immunogenicity properties of the present protease
conjugates, the protease
conjugates may further be used in applications which have historically
minimally benefited from
the use of proteases. Examples of such applications include those in which the
protease
conjugate necessarily comes in close contact with mammalian skin (especially
human skin), such
as with the use of personal care compositions.
Cleaning Compositions
The protease conjugates may be utilized in cleaning compositions including,
but not
limited to, laundry compositions, hard surface cleansing compositions, light
duty cleaning
compositions including dish cleansing compositions, and automatic dishwasher
detergent
compositions.
The cleaning compositions herein comprise an effective amount of one or more
protease
conjugates of the present invention and a cleaning composition carrier.
As used herein, "effective amount of protease conjugate", or the like, refers
to the
quantity of protease conjugate necessary to achieve the proteolytic activity
necessary in the
specific cleaning composition. Such effective amounts are readily ascertained
by one of ordinary
skill in the art and is based on many factors, such as the particular protease
conjugate used, the
cleaning application, the specific composition of the cleaning composition,
and whether a liquid
22
W~ 01/07577 CA 02379723 2002-O1-17 pCT/US00/18854
or dry (e.g., granular, bar) composition is required, and the like.
Preferably, the cleaning
compositions comprise from about 0.0001% to about 10%, more preferably from
about 0.001%
to about 1 %, and most preferably from about 0.01 % to about 0.1 % of one or
more protease
conjugates of the present invention. Several examples of various cleaning
compositions wherein
the protease conjugates may be employed are discussed in further detail below.
In addition to the present protease conjugates, the present cleaning
compositions further
comprise a cleaning composition carrier comprising one or more cleaning
composition materials
compatible with the protease conjugate. The term "cleaning composition
material", as used
herein, means any material selected for the particular type of cleaning
composition desired and
the form of the product (e.g., liquid, granule, bar, spray, stick, paste,
gel), which materials are
also compatible with the protease conjugate used in the composition. The
specific selection of
cleaning composition materials is readily made by considering the surface
material to be cleaned,
the desired form of the composition for the cleaning condition during use
(e.g., through the wash
detergent use). The term "compatible", as used herein, means the cleaning
composition materials
do not reduce the proteolytic activity of the protease conjugate to such an
extent that the protease
is not effective as desired during normal use situations. Specific cleaning
composition materials
are exemplified in detail hereinafter.
The protease conjugates of the present invention may be used in a variety of
detergent
compositions wherein high sudsing and good cleansing is desired. Thus the
protease conjugates
can be used with various conventional ingredients to provide fully-formulated
hard-surface
cleaners, dishwashing compositions, fabric laundering compositions, and the
like. Such
compositions can be in the form of liquids, granules, bars, and the like. Such
compositions can
be formulated as "concentrated" detergents which contain as much as from about
30% to about
60% by weight of surfactants.
The cleaning compositions herein may optionally, and preferably, contain
various
surfactants (e.g., anionic, nonionic, or zwitterionic surfactants). Such
surfactants arc typically
present at levels of from about 5% to about 35% of the compositions.
Nonlimiting examples of surfactants useful herein include the conventional C11-
C18
alkyl benzene sulfonates and primary and random alkyl sulfates, the C10-Clg
secondary (2,3)
alkyl sulfates of the formulas CH3(CH2)X(CHOS03)-M+)CH3 and CH3(CH2)y(CHOS03-
M+)
CH2CH3 wherein x and (y+1) are integers of at least about 7, preferably at
least about 9, and M
is a water-solubilizing cation, especially sodium, the C10-Clg alkyl alkoxy
sulfates (especially
23
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
EO 1-5 ethoxy sulfates), C10-Clg alkyl alkoxy carboxylates (especially the EO
1-5
ethoxycarboxylates), the C 10-C 1 g alkyl polyglycosides, and their
corresponding sulfated
polyglycosides, C 12-C 1 g a-sulfonated fatty acid esters, C 12-C 1 g alkyl
and alkyl phenol
alkoxylates (especially ethoxylates and mixed ethoxy/propoxy), C12-Clg
betaines and
sulfobetaines ("sultaines"), C 10-C 1 g amine oxides, and the like. The alkyl
alkoxy sulfates (AES)
and alkyl alkoxy carboxylates (AEC) are preferred herein. The use of such
surfactants in
combination with the amine oxide and / or betaine or sultaine surfactants is
also preferred,
depending on the desires of the formulator. Other conventional useful
surfactants are listed in
standard texts. Particularly useful surfactants include the C10-Clg N-methyl
glucamides
disclosed in U.S. Pat. No. 5, 194,639, Connor et al., issued March 16, 1993.
A wide variety of other ingredients useful in detergent cleaning compositions
can be
included in the compositions herein including, for example, other active
ingredients, carriers,
hydrotropes, processing aids, dyes or pigments, and solvents for liquid
formulations. If an
additional increment of sudsing is desired, suds boosters such as the C10-C16
alkolamides can be
incorporated into the compositions, typically at about 1% to about 10% levels.
The C10-C14
monoethanol and diethanol amides illustrate a typical class of such suds
boosters. Use of such
suds boosters with high sudsing adjunct surfactants such as the amine oxides,
betaines and
sultaines noted above is also advantageous. If desired, soluble magnesium
salts such as MgCl2,
MgS04, and the like, can be added at levels of, typically, from about 0.1% to
about 2%, to
provide additional sudsing.
The liquid detergent compositions herein may contain water and other solvents
as
carriers. Low molecular weight primary or secondary alcohols exemplified by
methanol, ethanol,
propanol, and iso-propanol are suitable. Monohydric alcohols are preferred for
solubilizing
surfactants, but polyols such as those containing from about 2 to about 6
carbon atoms and from
about 2 to about 6 hydroxy groups (e.g., 1,3-propanediol, ethylene glycol,
glycerine, and 1,2-
propanediol) can also be used. The compositions may contain from about 5% to
about 90%,
typically from about 10% to about 50% of such carriers.
The detergent compositions herein will preferably be formulated such that
during use in
aqueous cleaning operations, the wash water will have a pH between about 6.8
and about 11.
Finished products thus are typically formulated at this range. Techniques for
controlling pH at
recommended usage levels include the use of, for example, buffers, alkalis,
and acids. Such
techniques are well known to those skilled in the art.
24
W~ X1/07577 CA 02379723 2002-O1-17 pCT~S00/18854
When formulating the hard surface cleaning compositions and fabric cleaning
compositions of the present invention, the formulator may wish to employ
various builders at
levels from about 5% to about 50% by weight. Typical builders include the 1-10
micron zeolites,
polycarboxylates such as citrate and oxydisuccinates, layered silicates,
phosphates, and the like.
Other conventional builders are listed in standard formularies.
Likewise, the formulator may wish to employ various additional enzymes, such
as
cellulases, lipases, amylases, and proteases in such compositions, typically
at levels of from about
0.001 % to about 1 % by weight. Various detersive and fabric care enzymes are
well-known in the
laundry detergent art.
Various bleaching compounds, such as the percarbonates, perborates and the
like, can be
used in such compositions, typically at levels from about 1% to about 15% by
weight. If desired,
such compositions can also contain bleach activators such as tetraacetyl
ethylenediamine,
nonanoyloxybenzene sulfonate, and the like, which are also known in the art.
Usage levels
typically range from about 1 % to about 10% by weight.
Soil release agents, especially of the anionic oligoester type, chelating
agents, especially
the aminophosphonates and ethylenediaminedisuccinates, clay soil removal
agents, especially
ethoxylated tetraethylene pentamine, dispersing agents, especially
polyacrylates and
polyasparatates, brighteners, especially anionic brighteners, suds
suppressors, especially silicones
and secondary alcohols, fabric softeners, especially smectite clays, and the
like can all be used in
such compositions at levels ranging from about 1% to about 35% by weight.
Standard
formularies and published patents contain multiple, detailed descriptions of
such conventional
materials.
Enzyme stabilizers may also be used in the cleaning compositions. Such enzyme
stabilizers include propylene glycol (preferably from about 1% to about 10%),
sodium formate
(preferably from about 0.1 % to about 1 %) and calcium formate (preferably
from about 0.1 % to
about 1%).
The present variants are useful in hard surface cleaning compositions. As used
herein
"hard surface cleaning composition" refers to liquid and granular detergent
compositions for
cleaning hard surfaces such as floors, walls, bathroom tile, and the like.
Hard surface cleaning
compositions of the present invention comprise an effective amount of one or
more protease
conjugates of the present invention, preferably from about 0.001% to about
10%, more preferably
from about 0.01% to about 5%, and more preferably still from about 0.05% to
about 1% by
weight of protease conjugate of the composition. In addition to comprising one
or more of the
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
protease conjugates, such hard surface cleaning compositions typically
comprise a surfactant and
a water-soluble sequestering builder. In certain specialized products such as
spray window
cleaners, however, the surfactants are sometimes not used since they may
produce a filmy and /
or streaky residue on the glass surface.
The surfactant component, when present, may comprise as little as 0.1% of the
compositions herein, but typically the compositions will contain from about
0.25% to about 10%.,
more preferably from about 1% to about 5% of surfactant.
Typically the compositions will contain from about 0.5% to about 50% of a
detergency
builder, preferably from about 1 % to about 10%.
Preferably the pH should be in the range of about 7 to 12. Conventional pH
adjustment
agents such as sodium hydroxide, sodium carbonate, or hydrochloric acid can be
used if
adjustment is necessary.
Solvents may be included in the compositions. Useful solvents include, but are
not
limited to, glycol ethers such as diethyleneglycol monohexyl ether,
diethyleneglycol monobutyl
ether, ethyleneglycol monobutyl ether, ethyleneglycol monohexyl ether,
propyleneglycol
monobutyl ether, dipropyleneglycol monobutyl ether, and diols such as 2,2,4-
trimethyl-1,3-
pentanediol and 2-ethyl-1,3-hexanediol. When used, such solvents are typically
present at levels
of from about 0.5% to about 15%, more preferably from about 3% to about 11%.
Additionally, highly volatile solvents such as iso-propanol or ethanol can be
used in the
present compositions to facilitate faster evaporation of the composition from
surfaces when the
surface is not rinsed after "full strength" application of the composition to
the surface. When
used, volatile solvents are typically present at levels of from about 2% to
about 12% in the
compositions.
Examples 7 - 12
Liquid Hard Surface Cleaning Compositions
Ex.7 Ex.8 Ex.9 Ex.lO Ex.ll Ex.
l2
Protease Conjugate 0.05 0.50 0.02 0.03 0.30 0.05
of % % % % %
Example 3
EDTA - - 2.90 2.90 - -
% %
Sodium Citrate - - - - 2.90 2.90
%
NaC,~ Alkyl-benzene 1.95 - 1.95 - 1.95 -
sulfonate % % %
26
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
NaC,~ Alkylsulfate - 2.20 - 2.20 - 2.20
% %
NaCI~ (ethoxy) sulfate- 2.20 - 2.20 - 2.20
% %
C,Z Dimethylamine - 0.50 - 0.50 - 0.50
oxide % %
Sodium cumene sulfonate1.30 - 1.30 - 1.30 -
% % %
Hexyl Carbitol 6.30 6.30 6.30 6.30 6.30 6.30
% % % % %
Water 90.4 88.3 87.53 85.87 87.25 85.85
% % % % %
All formulas are adjusted to pH 7.
In another embodiment of the present invention, dishwashing compositions
comprise one
or more variants of the present invention. As used herein, "dishwashing
composition" refers to
all forms of compositions for cleaning dishes including, but not limited to,
granular and liquid
forms.
Examples 13 - 16
Liquid Dish Detergent
Ex. l3 Ex. Ex.lS Ex. l6
l4
Protease Conjugate of Example0.05 0.50 0.02 0.40
1 % % %
C1z - C,~ N-methyl glucamide0.90 0.90 0.90 0.90
% % %
C, ~ ethoxy ( 1 ) sulfate 12.0 12.0 12.0 12.0
% % %
2-Methyl undecanoic acid 4.50 4.50 4.50 4.50
% % %
C1~ ethoxy (2) carboxylate4.50 4.50 4.50 4.50
% % %
C,~ alcohol ethoxylate 3.00 3.00 3.00 3.00
(4) % % %
C,2 amine oxide 3.00 3.00 3.00 3.00
% % %
Sodium cumene sulfonate 2.00 2.00 2.00 2.00
% % %
Ethanol 4.00 4.00 4.00 4.00
% % %
Mg2+ (as MgCl2) 0.20 0.20 0.20 0.20
% % %
Ca2+ (as CaClz) 0.40 0.40 0.40 0.40
% % %
Water 65.45 65 % 65.48 65.1
% %
All formulas are adjusted to pH 7.
27
W~ 01/07$77 CA 02379723 2002-O1-17 pCT~S00/18854
Examples 17 - 19
Liquid Fabric Cleaning Compositions
Ex. Ex. Ex. l9
l7 l8
Protease Conjugate of Example 0.05 0.03 0.30
4 % %
Sodiuam C,Z - C,4 alkyl sulfate 20.0 20.0 20.0
% %
2-Butyl octanoic acid 5.0 5.0 5.0
% %
Sodium citrate 1.0 1.0 1.0
% %
C,o Alcohol ethoxylate (3) 13.0 13.0 13.0
% %
Monoethanolamine 2.50 2.50 2.50
% %
Water/propylene glycol/ethanol 58.45 58.47 58.20
(100:1:1) % %
Personal Care Compositions
The present protease conjugates are particularly suited for use in personal
care
compositions such as, for example, leave-on and rinse-off hair conditioners,
shampoos, leave-on
and rinse-off acne compositions, facial milks and conditioners, shower gels,
soaps, foaming and
non-foaming facial cleansers, cosmetics, hand, facial, and body lotions,
moisturizers, patches, and
masks, leave-on facial moisturizers, cosmetic and cleansing wipes, oral care
compositions,
catamenials, and contact lens care compositions. The present personal care
compositions
comprise one or more protease conjugates of the present invention and a
personal care carrier.
To illustrate, the present protease conjugates are suitable for inclusion in
the
compositions described in the following references: U.S. Pat. No. 5,641,479,
Linares et al.,
issued June 24, 1997 (skin cleansers); U.S. Pat. No. 5,599,549, Wivell et al.,
issued February 4,
1997 (skin cleansers); U.S. Pat. No. 5,585,104, Ha et al., issued December 17,
1996 (skin
cleansers); U.S. Pat. No. 5,540,852, Kefauver et al., issued July 30, 1996
(skin cleansers); U.S.
Pat. No. 5,510,050, Dunbar et al., issued April 23, 1996 (skin cleansers);
U.S. Pat. No. 5,612,324,
Guano Lin et al., issued March 18, 1997 (anti-acne preparations); U.S. Pat.
No. 5,587,176,
Warren et al., issued December 24, 1996 (anti-acne preparations); U.S. Pat.
No. 5,549,888,
Venkateswaran, issued August 27, 1996 (anti-acne preparations); U.S. Pat. No.
5,470,884,
Corless et al., issued November 28, 1995 (anti-acne preparations); U.S. Pat.
No. 5,650,384,
Gordon et al., issued July 22, 1997 (shower gels); U.S. Pat. No. 5,607,678,
Moore et al., issued
March 4, 1997 (shower gels); U.S. Pat. No. 5,624,666, Coffindaffer et al.,
issued April 29, 1997
(hair conditioners and / or shampoos); U.S. Pat. No. 5,618,524, Bolich et al.,
issued April 8, 1997
(hair conditioners and / or shampoos); U.S. Pat. No. 5,612,301, Inman, issued
March 18, 1997
28
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
(hair conditioners and / or shampoos); U.S. Pat. No. 5,573,709, Wells, issued
November 12, 1996
(hair conditioners and / or shampoos); U.S. Pat. No. 5,482,703, Pins, issued
January 9, 1996
(hair conditioners and / or shampoos); U.S. Pat. No. Re. 34,584, Grote et al.,
Reissued April 12,
1994 (hair conditioners and / or shampoos); U.S. Pat. No. 5,641,493, Date et
al., issued June 24,
1997 (cosmetics); U.S. Pat. No. 5,605,894, Blank et al., issued February 25,
1997 (cosmetics);
U.S. Pat. No. 5,585,090, Yoshioka et al., issued December 17, 1996
(cosmetics); U.S. Pat. No.
4,939,179, Cheney et al., issued July 3, 1990 (hand, face, and / or body
lotions); U.S. Pat. No.
5,607,980, McAtee et al., issued March 4, 1997 (hand, face, and / or body
lotions); U.S. Pat. No.
4,045,364, Richter et al., issued August 30, 1977 (cosmetic and cleansing
wipes); European
Patent Application, EP 0 619 074, Touchet et al., published October 12, 1994
(cosmetic and
cleansing wipes); U.S. Pat. No. 4,975,217, Brown-Skrobot et al., issued
December 4, 1990
(cosmetic and cleansing wipes); U.S. Pat. No. 5,096,700, Seibel, issued March
17, 1992 (oral
cleaning compositions); U.S. Pat. No. 5,028,414, Sampathkumar, issued July 2,
1991 (oral
cleaning compositions); U.S. Pat. No. 5,028,415, Benedict et al., issued July
2, 1991 (oral
cleaning compositions); U.S. Pat. No. 5,028,415, Benedict et al., issued July
2, 1991 (oral
cleaning compositions); U.S. Pat. No. 4,863,627, Davies et al., September 5,
1989 (contact lens
cleaning solutions); U.S. Pat. No. Re. 32,672, Huth et al, reissued May 24,
1988 (contact lens
cleaning solutions); and U.S. Pat. No. 4,609,493, Schafer, issued September 2,
1986 (contact lens
cleaning solutions).
To further illustrate oral cleaning compositions of the present invention, a
pharmaceutically-acceptable amount of one or more protease conjugates of the
present invention
is included in compositions useful for removing proteinaceous stains from
teeth or dentures. As
used herein, "oral cleaning compositions" refers to dentifrices, toothpastes,
toothgels,
toothpowders, mouthwashes, mouth sprays, mouth gels, chewing gums, lozenges,
sachets, tablets,
biogels, prophylaxis pastes, dental treatment solutions, and the like.
Preferably, the oral cleaning
compositions comprise from about 0.0001% to about 20% of one or more protease
conjugates of
the present invention, more preferably from about 0.001 % to about 10%, more
preferably still
from about 0.01% to about 5%, by weight of the composition, and a
pharmaceutically-acceptable
carrier. As used herein, "pharmaceutically-acceptable" means that drugs,
medicaments, or inert
ingredients which the term describes are suitable for use in contact with the
tissues of humans
and lower animals without undue toxicity, incompatibility, instability,
irritation, allergic
response, and the like, commensurate with a reasonable benefit / risk ratio.
29
WO 01/07577 CA 02379723 2002-0l-17 pCT/US00/18854
Typically, the pharmaceutically-acceptable oral cleaning Garner components of
the oral
cleaning components of the oral cleaning compositions will generally comprise
from about SO%
to about 99.99%, preferably from about 65% to about 99.99%, more preferably
from about 65%
to about 99%, by weight of the composition.
The pharmaceutically-acceptable carrier components and optional components
which
may be included in the oral cleaning compositions of the present invention are
well known to
those skilled in the art. A wide variety of composition types, carrier
components and optional
components useful in the oral cleaning compositions are disclosed in the
references cited
hereinabove.
In another embodiment of the present invention, denture cleaning compositions
for
cleaning dentures outside of the oral cavity comprise one or more protease
conjugates of the
present invention. Such denture cleaning compositions comprise an effective
amount of one or
more of the protease conjugates, preferably from about 0.0001% to about 50%,
more preferably
from about 0.001% to about 35%, more preferably still from about 0.01% to
about 20%, by
weight of the composition, and a denture cleansing carrier. Various denture
cleansing
composition formats such as effervescent tablets and the like are well known
in the art (see~e.~.,
U.S. Pat. No. 5,055,305, Young), and are generally appropriate for
incorporation of one or more
of the protease conjugates for removing proteinaceous stains from dentures.
In another embodiment of the present invention, contact lens cleaning
compositions
comprise one or more protease conjugates of the present invention. Such
contact lens cleaning
compositions comprise an effective amount of one or more of the protease
conjugates, preferably
from about 0.01% to about 50% of one or more of the protease conjugates, more
preferably from
about 0.01% to about 20%, more preferably still from about 1% to about 5%, by
weight of the
composition, and a contact lens cleaning carrier. Various contact lens
cleaning composition
formats such as tablets, liquids, and the like are well known in the art and
are generally
appropriate for incorporation of one or more protease conjugates of the
present invention for
removing proteinaceous stains from contact lens.
WO X1/07577 CA 02379723 2002-O1-17 pCT/US00/18854
Examples 20 - 23
Contact Lens Cleaning Solution
Ex.20 Ex.21 Ex.22 Ex.23
Protease Conjugate of Example0.01 % 0.5 0.1 % 2.0
%
Glucose 50.0 % 50.0 50.0 50.0
% %
Nonionic surfactant (polyoxyethlene2.0 % 2.0 2.0 % 2.0
- %
polyoxypropylene copolymer)
Anionic surfactant (polyoxyethylene1.0 % 1.0 1.0 % 1.0
- %
alkylphenylether sodium
sulfricester)
Sodium Chloride 1.0 % 1.0 1.0 % 1.0
%
Borax 0.30 % 0.30 0.30 0.30
% %
Water 45.69 45.20 45.60 43.70
% % %
Examples 24 - 27
Bodywash Products
Ex.24 Ex.25 Ex.26 Ex.27
Water 62.62 65.72 57.72 60.72
% % %
Disodium EDTA 0.2 % 0.2 0.2 % 0.2
%
Glycerine 3.0 % 3.0 3.0 % 3.0
%
Polyquaternium 10 0.4 % 0.4 0.4 % 0.4
%
Sodium laureth sulphate 12.0 12.0 12.0 12.0
% % %
Cocamide MEA 2.8 % 2.8 2.8 % 2.8
%
Sodium lauraphoacetate 6.0 % 6.0 6.0 % 6.0
%
Myristic Acid 1.6 % 1.6 1.6 % 1.6
%
Magnesium sulphate heptahydrate0.3 % 0.3 0.3 % 0.3
%
Trihydroxystearin 0.5 % 0.5 0.5 % 0.5
%
PEG-6 caprylic / capric triglycerides3.0 % - - -
Sucrose polyesters of cottonate3.0 % - - -
fatty acid
Sucrose polyesters of behenate3.0 % - 4.0 % -
fatty acid
Petrolatum - 4.0 8.0 % -
%
Mineral Oil - - - 6.0
DMDM Hydantoin 0.08 0.08 0.08 0.08
% % %
31
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
Protease Conjugate of Example0.1 % 2.0 % 2.0 5.0
6 %
Citric Acid 1.40 % 1.40 1.40 1.40
% %
Examples 28 - 31
Facewash Products
Ex.28 Ex.29 Ex.30 Ex.31
Water 66.52 65.17 68.47 68.72
% % %
Disodium EDTA 0.1 % 0.1 % 0.2 0.2
%
Citric Acid - - 1.4 1.4
%
Sodium Laureth-3 Sulfate 3.0 % 3.5 % - -
Sodium Laureth-4 Carboxylate3.0 % 3.5 % - -
Laureth-12 1.0 % 1.2 % - -
Polyquaternium 10 - - 0.4 0.4
%
Polyquaternium 25 0.3 % 0.3 % - -
Glycerine 3.0 % 3.0 % 3.0 3.0
%
Sodium Lauroamphoacetate - - 6.0 6.0
%
Lauric Acid 6.0 % 6.0 % 3.0 3.0
%
Myristic Acid - - 3.0 3.0
%
Magnesium sulphate heptahydrate2.3 % 2.0 % 2.0 2.0
%
Triethanol amine 4.0 % 4.0 % 4.0 4.0
%
Trihydroxystearin 0.5 % 0.5 % 0.5 0.5
%
Sucrose polyesters of behenate2.0 % 2.0 % - -
fatty acid
Sucrose polyesters of cottonate3.0 % 2.0 % - -
fatty acid
PEG-6 caprylic / capric triglycerides- - - 2.0
Petrolatum - - 4.0 -
%
Mineral Oil - - - 2.0
Cocamidopropyl betaine 2.0 % 3.0 % 1.8 1.8
%
Lauryl dimethylamine oxide 1.0 % 1.2 % 1.2 1.2
%
Dex Panthenol 1.0 % 0.25 0.25 -
% %
DMDM Hydantoin 0.08 0.08 0.08 0.08
% % %
Protease Conjugate of Example1.0 % 2.0 % 0.5 0.5
2 %
Fragrance 0.2 % 0.2 % 0.2 0.2
%
32
W~ X1/07577 CA 02379723 2002-O1-17 pCT/~1500/18854
Examples 32 - 33
Leave-on Skin Moisturizing Composition
Ex. 32 Ex. 33
Glycerine S.0 % -
Stearic acid 3.0
C"-,3Isoparaffm 2.0 % -
Glycol stearate 1.5 % -
Propylene glycol - 3.0
Mineral oil 1.0 % 10.0
Sesame oil - 7.0
Petrolatum - 1.8
Triethanolamine 0.7 % -
Cetyl acetate 0.65 % -
Glyceryl stearate 0.48 % 2.0
TEA stearate - 2.5
Cetyl alcohol 0.47 % -
Lanolin alcohol - 1.8
DEA - cetyl phosphate 0.25 % -
Methylparaben 0.2 % 0.2
Propylparaben 0.12 % 0.1
Carbomer 934 0.11 % -
Disodium EDTA 0.1 % -
Protease Conjugate of Example0.1 % 0.5
4
Water 84.32 % 71.1
33
CA 02379723 2002-O1-17
WO 01/07577 PCT/LJS00/18854
Example 34
Cleansing Wipe Composition
Propylene Glycol 1.0
Ammonium lauryl sulfate 0.6
Succinic acid 4.0
Sodium succinate 3.2
0
Triclosan~ 0.15 /o
Protease Conjugate of Example 0.05
1
Water 91.0
The above composition is impregnated onto a woven absorbent sheet comprised of
cellulose and /
or polyester at about 250%, by weight of the absorbent sheet.
34
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
SEQUENCE LISTING
<110> The Procter & Gamble Company
<120> PROTEASE CONJUGATES HAVING STERICALLY PROTECTED EPITOPE
REGIONS
<130> Epitopeprotection
<140> PCT/US00/
<141> 2000-07-11
<160> 1
<170> PatentIn Ver. 2.0
<210> 1
<211> 275
<212> PRT
<213> Bacillus amyloliquefaciens
<400> 1
Ala Gln Ser Val Pro Tyr Gly Val Ser Gln Ile Lys Ala Pro Ala Leu
1 5 10 15
His Ser Gln Gly Tyr Thr Gly Ser Asn Val Lys Val Ala Val Ile Asp
20 25 30
Ser Gly Ile Asp Ser Ser His Pro Asp Leu Lys Val Ala Gly Gly Ala
35 40 45
Ser Met Val Pro Ser Glu Thr Asn Pro Phe Gln Asp Asn Asn Ser His
50 55 60
Gly Thr His Val Ala Gly Thr Val Ala Ala Leu Asn Asn Ser Ile Gly
65 70 75 80
Val Leu Gly Val Ala Pro Ser Ala Ser Leu Tyr Ala Val Lys Val Leu
85 90 95
Gly Ala Asp Gly Ser Gly Gln Tyr Ser Trp Ile Ile Asn Gly Ile Glu
100 105 110
Trp Ala Ile Ala Asn Asn Met Asp Val Ile Asn Met Ser Leu Gly Gly
115 120 125
Pro Ser Gly Ser Ala Ala Leu Lys Ala Ala Val Asp Lys Ala Val Ala
130 135 140
Ser Gly Val Val Val Val Ala Ala Ala Gly Asn Glu Gly Thr Ser Gly
145 150 155 160
Ser Ser Ser Thr Val Gly Tyr Pro Gly Lys Tyr Pro Ser Val Ile Ala
165 170 175
Val Gly Ala Val Asp Ser Ser Asn Gln Arg Ala Ser Phe Ser Ser Val
180 185 190
Gly Pro Glu Leu Asp Val Met Ala Pro Gly Val Ser Ile Gln Ser Thr
195 200 205
Leu Pro Gly Asn Lys Tyr Gly Ala Tyr Asn Gly Thr Ser Met Ala Ser
210 215 220
Pro His Val Ala Gly Ala Ala Ala Leu Ile Leu Ser Lys His Pro Asn
225 230 235 240
1
CA 02379723 2002-O1-17
WO 01/07577 PCT/US00/18854
Trp Thr Asn Thr Gln Val Arg Ser Ser Leu Glu Asn Thr Thr Thr Lys
245 250 255
Leu Gly Asp Ser Phe Tyr Tyr Gly Lys Gly Leu Ile Asn Val Gln Ala
260 265 270
Ala Ala Gln
275
2
